幹細胞治療市場。幹細胞治療市場:細胞源別(脂肪組織、骨髄、神経、胚・コード、IPSC、PPSC)、タイプ別(自己由来、同種)、用途別(がん、糖尿病、筋骨格系疾患、心血管、消化器疾患)、エンドユーザー別(病院・診療所、外来手術センター、学術・研究センター)、地域別(南北アメリカ、ヨーロッパ、アジア太平洋、その他の地域)の情報-2027年までの予測Stem Cell Therapy Market: Information by Cell Source (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord, IPSCs, and PPSCs), by Type (Autologous and Allogenic), by Application (Cancer, Diabetes, Musculoskeletal Disorders, Cardiovascular, Gastrointestinal Diseases), by End User (Hospitals & Clinics, Ambulatory Surgical Centers, Academic & Research Centers), and by Region (Americas, Europe, Asia-Pacific, and Rest of the World)Forecast till 2027 COVID 19 Impacts We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you underst... もっと見る
サマリーCOVID 19 ImpactsWe are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights. 目次TABLE OF CONTENTCHAPTER 1. REPORT PROLOGUE CHAPTER 2. MARKET INTRODUCTION 2.1 DEFINITION 2.2 SCOPE OF THE STUDY 2.2.1 RESEARCH OBJECTIVE 2.2.2 ASSUMPTIONS 2.2.3 LIMITATIONS CHAPTER 3. RESEARCH METHODOLOGY 3.1 INTRODUCTION 3.2 PRIMARY RESEARCH 3.3 SECONDARY RESEARCH 3.4 MARKET SIZE ESTIMATION CHAPTER 4. MARKET DYNAMICS 4.1 DRIVERS 4.2 RESTRAINTS 4.3 OPPORTUNITIES 4.4 CHALLENGES 4.5 MACROECONOMIC INDICATORS 4.6 TECHNOLOGY TRENDS & ASSESSMENT CHAPTER 5. MARKET FACTOR ANALYSIS 5.1 PORTER’S FIVE FORCES ANALYSIS 5.1.1 BARGAINING POWER OF SUPPLIERS 5.1.2 BARGAINING POWER OF BUYERS 5.1.3 THREAT OF NEW ENTRANTS 5.1.4 THREAT OF SUBSTITUTES 5.1.5 INTENSITY OF RIVALRY 5.2 VALUE CHAIN ANALYSIS 5.3 INVESTMENT FEASIBILITY ANALYSIS 5.4 PRICING ANALYSIS CHAPTER 6. GLOBAL STEM CELL THERAPY MARKET, BY TYPE 6.1 INTRODUCTION 6.2 ALLOGENEIC 6.3 AUTOLOGOUS CHAPTER 7. GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION 7.1 INTRODUCTION 7.2 MEDICINE 7.3 CARDIOVASCULAR DISEASES 7.4 BONE REGENERATION 7.5 NEURODEGENERATIVE DISORDERS 7.6 WOUND HEALING 7.7 TREATMENT OF EYES 7.8 HEMATOPOIETIC DISORDERS 7.9 METABOLIC DISORDERS 7.10 CANCER 7.11 IMMUNODEFICIENCY 7.12 DIABETES CHAPTER 8. GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE 8.1 INTRODUCTION 8.2 ADIPOSE TISSUE 8.3 BONE MARROW 8.3 NEURAL 8.4 EMBRYO/CORD BLOOD-DERIVED 8.5 IPSCS CHAPTER 9. GLOBAL STEM CELL THERAPY MARKET, BY END -USER 9.1 INTRODUCTION 9.2 BIOTECHNOLOGY COMPANIES 9.3 HOSPITALS & RESEARCH INSTITUTES 9.4 CONTRACT RESEARCH ORGANIZATIONS 9.5 STEM CELL BANKS CHAPTER 10. GLOBAL STEM CELL THERAPY MARKET, BY REGION 10.1 INTRODUCTION 10.2 AMERICA 10.2.1 NORTH AMERICA 10.2.1.1 US 10.2.1.2 CANADA 10.2.2 SOUTH AMERICA 10.3 EUROPE 10.3.1 WESTERN EUROPE 10.3.1.1 GERMANY 10.3.1.2 FRANCE 10.3.1.3 ITALY 10.3.1.4 SPAIN 10.3.1.5 UK 10.3.1.6 REST OF WESTERN EUROPE 10.3.2 EASTERN EUROPE 10.4 ASIA-PACIFIC 10.4.1 JAPAN 10.4.2 CHINA 10.4.3 INDIA 10.4.4 AUSTRALIA 10.4.5 REPUBLIC OF KOREA 10.4.6 REST OF ASIA-PACIFIC 10.5 MIDDLE EAST & AFRICA 10.5.1 UNITED ARAB EMIRATES 10.5.2 SAUDI ARABIA 10.5.3 OMAN 10.5.4 KUWAIT 10.5.5 QATAR 10.5.6 REST OF THE MIDDLE EAST & AFRICA CHAPTER 11. COMPANY LANDSCAPE 11.1 INTRODUCTION 11.2 MARKET SHARE ANALYSIS 11.3 KEY DEVELOPMENT & STRATEGIES 11.3.1 KEY DEVELOPMENTS CHAPTER 12 COMPANY PROFILES 12.1 OSIRIS THERAPEUTICS, INC. 12.1.1 COMPANY OVERVIEW 12.1.2 PRODUCT TYPE OVERVIEW 12.1.3 FINANCIALS 12.2.4 KEY DEVELOPMENTS 12.1.5 SWOT ANALYSIS 12.2 MEDIPOST CO., LTD. 12.2.1 COMPANY OVERVIEW 12.2.2 PRODUCT TYPE OVERVIEW 12.2.3 FINANCIAL OVERVIEW 12.2.4 KEY DEVELOPMENTS 12.2.5 SWOT ANALYSIS 12.3 ANTEROGEN CO., LTD. 12.3.1 COMPANY OVERVIEW 12.3.2 PRODUCT TYPE OVERVIEW 12.3.3 FINANCIAL OVERVIEW 12.3.4 KEY DEVELOPMENT 12.3.5 SWOT ANALYSIS 12.4 PHARMICELL CO., LTD. 12.4.1 COMPANY OVERVIEW 12.4.2 PRODUCT TYPE/BUSINESS SEGMENT OVERVIEW 12.4.3 FINANCIAL OVERVIEW 12.4.4 KEY DEVELOPMENT 12.4.5 SWOT ANALYSIS 12.5 HOLOSTEM TERAPIE AVANZATE S.R.L. 12.5.1 COMPANY OVERVIEW 12.5.2 PRODUCT TYPE OVERVIEW 12.5.3 FINANCIAL OVERVIEW 12.5.4 KEY DEVELOPMENTS 12.5.5 SWOT ANALYSIS 12.6 JCR PHARMACEUTICALS CO., LTD. 12.6.1 COMPANY OVERVIEW 12.6.2 PRODUCT TYPE OVERVIEW 12.6.3 FINANCIAL OVERVIEW 12.6.4 KEY DEVELOPMENTS 12.6.5 SWOT ANALYSIS 12.7 NUVASIVE, INC 12.7.1 OVERVIEW 12.7.2 PRODUCT TYPE OVERVIEW 12.7.3 FINANCIALS 12.7.4 KEY DEVELOPMENTS 12.7.5 SWOT ANALYSIS 12.8 RTI SURGICAL, INC. 12.8.1 OVERVIEW 12.8.2 PRODUCT TYPE OVERVIEW 12.8.3 FINANCIALS 12.8.4 KEY DEVELOPMENTS 12.8.5 SWOT ANALYSIS 12.9 ALLOSOURCE 12.9.1 OVERVIEW 12.9.2 PRODUCT TYPE OVERVIEW 12.9.3 FINANCIALS 12.9.4 KEY DEVELOPMENTS 12.9.5 SWOT ANALYSIS 12.10 THERMO FISHER SCIENTIFIC 12.10.1 OVERVIEW 12.10.2 PRODUCT TYPE OVERVIEW 12.10.3 FINANCIALS 12.10.4 KEY DEVELOPMENTS 12.10.5 SWOT ANALYSIS 12.11 OTHERS CHAPTER 14 APPENDIX
SummaryCOVID 19 ImpactsWe are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights. Table of ContentsTABLE OF CONTENTCHAPTER 1. REPORT PROLOGUE CHAPTER 2. MARKET INTRODUCTION 2.1 DEFINITION 2.2 SCOPE OF THE STUDY 2.2.1 RESEARCH OBJECTIVE 2.2.2 ASSUMPTIONS 2.2.3 LIMITATIONS CHAPTER 3. RESEARCH METHODOLOGY 3.1 INTRODUCTION 3.2 PRIMARY RESEARCH 3.3 SECONDARY RESEARCH 3.4 MARKET SIZE ESTIMATION CHAPTER 4. MARKET DYNAMICS 4.1 DRIVERS 4.2 RESTRAINTS 4.3 OPPORTUNITIES 4.4 CHALLENGES 4.5 MACROECONOMIC INDICATORS 4.6 TECHNOLOGY TRENDS & ASSESSMENT CHAPTER 5. MARKET FACTOR ANALYSIS 5.1 PORTER’S FIVE FORCES ANALYSIS 5.1.1 BARGAINING POWER OF SUPPLIERS 5.1.2 BARGAINING POWER OF BUYERS 5.1.3 THREAT OF NEW ENTRANTS 5.1.4 THREAT OF SUBSTITUTES 5.1.5 INTENSITY OF RIVALRY 5.2 VALUE CHAIN ANALYSIS 5.3 INVESTMENT FEASIBILITY ANALYSIS 5.4 PRICING ANALYSIS CHAPTER 6. GLOBAL STEM CELL THERAPY MARKET, BY TYPE 6.1 INTRODUCTION 6.2 ALLOGENEIC 6.3 AUTOLOGOUS CHAPTER 7. GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION 7.1 INTRODUCTION 7.2 MEDICINE 7.3 CARDIOVASCULAR DISEASES 7.4 BONE REGENERATION 7.5 NEURODEGENERATIVE DISORDERS 7.6 WOUND HEALING 7.7 TREATMENT OF EYES 7.8 HEMATOPOIETIC DISORDERS 7.9 METABOLIC DISORDERS 7.10 CANCER 7.11 IMMUNODEFICIENCY 7.12 DIABETES CHAPTER 8. GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE 8.1 INTRODUCTION 8.2 ADIPOSE TISSUE 8.3 BONE MARROW 8.3 NEURAL 8.4 EMBRYO/CORD BLOOD-DERIVED 8.5 IPSCS CHAPTER 9. GLOBAL STEM CELL THERAPY MARKET, BY END -USER 9.1 INTRODUCTION 9.2 BIOTECHNOLOGY COMPANIES 9.3 HOSPITALS & RESEARCH INSTITUTES 9.4 CONTRACT RESEARCH ORGANIZATIONS 9.5 STEM CELL BANKS CHAPTER 10. GLOBAL STEM CELL THERAPY MARKET, BY REGION 10.1 INTRODUCTION 10.2 AMERICA 10.2.1 NORTH AMERICA 10.2.1.1 US 10.2.1.2 CANADA 10.2.2 SOUTH AMERICA 10.3 EUROPE 10.3.1 WESTERN EUROPE 10.3.1.1 GERMANY 10.3.1.2 FRANCE 10.3.1.3 ITALY 10.3.1.4 SPAIN 10.3.1.5 UK 10.3.1.6 REST OF WESTERN EUROPE 10.3.2 EASTERN EUROPE 10.4 ASIA-PACIFIC 10.4.1 JAPAN 10.4.2 CHINA 10.4.3 INDIA 10.4.4 AUSTRALIA 10.4.5 REPUBLIC OF KOREA 10.4.6 REST OF ASIA-PACIFIC 10.5 MIDDLE EAST & AFRICA 10.5.1 UNITED ARAB EMIRATES 10.5.2 SAUDI ARABIA 10.5.3 OMAN 10.5.4 KUWAIT 10.5.5 QATAR 10.5.6 REST OF THE MIDDLE EAST & AFRICA CHAPTER 11. COMPANY LANDSCAPE 11.1 INTRODUCTION 11.2 MARKET SHARE ANALYSIS 11.3 KEY DEVELOPMENT & STRATEGIES 11.3.1 KEY DEVELOPMENTS CHAPTER 12 COMPANY PROFILES 12.1 OSIRIS THERAPEUTICS, INC. 12.1.1 COMPANY OVERVIEW 12.1.2 PRODUCT TYPE OVERVIEW 12.1.3 FINANCIALS 12.2.4 KEY DEVELOPMENTS 12.1.5 SWOT ANALYSIS 12.2 MEDIPOST CO., LTD. 12.2.1 COMPANY OVERVIEW 12.2.2 PRODUCT TYPE OVERVIEW 12.2.3 FINANCIAL OVERVIEW 12.2.4 KEY DEVELOPMENTS 12.2.5 SWOT ANALYSIS 12.3 ANTEROGEN CO., LTD. 12.3.1 COMPANY OVERVIEW 12.3.2 PRODUCT TYPE OVERVIEW 12.3.3 FINANCIAL OVERVIEW 12.3.4 KEY DEVELOPMENT 12.3.5 SWOT ANALYSIS 12.4 PHARMICELL CO., LTD. 12.4.1 COMPANY OVERVIEW 12.4.2 PRODUCT TYPE/BUSINESS SEGMENT OVERVIEW 12.4.3 FINANCIAL OVERVIEW 12.4.4 KEY DEVELOPMENT 12.4.5 SWOT ANALYSIS 12.5 HOLOSTEM TERAPIE AVANZATE S.R.L. 12.5.1 COMPANY OVERVIEW 12.5.2 PRODUCT TYPE OVERVIEW 12.5.3 FINANCIAL OVERVIEW 12.5.4 KEY DEVELOPMENTS 12.5.5 SWOT ANALYSIS 12.6 JCR PHARMACEUTICALS CO., LTD. 12.6.1 COMPANY OVERVIEW 12.6.2 PRODUCT TYPE OVERVIEW 12.6.3 FINANCIAL OVERVIEW 12.6.4 KEY DEVELOPMENTS 12.6.5 SWOT ANALYSIS 12.7 NUVASIVE, INC 12.7.1 OVERVIEW 12.7.2 PRODUCT TYPE OVERVIEW 12.7.3 FINANCIALS 12.7.4 KEY DEVELOPMENTS 12.7.5 SWOT ANALYSIS 12.8 RTI SURGICAL, INC. 12.8.1 OVERVIEW 12.8.2 PRODUCT TYPE OVERVIEW 12.8.3 FINANCIALS 12.8.4 KEY DEVELOPMENTS 12.8.5 SWOT ANALYSIS 12.9 ALLOSOURCE 12.9.1 OVERVIEW 12.9.2 PRODUCT TYPE OVERVIEW 12.9.3 FINANCIALS 12.9.4 KEY DEVELOPMENTS 12.9.5 SWOT ANALYSIS 12.10 THERMO FISHER SCIENTIFIC 12.10.1 OVERVIEW 12.10.2 PRODUCT TYPE OVERVIEW 12.10.3 FINANCIALS 12.10.4 KEY DEVELOPMENTS 12.10.5 SWOT ANALYSIS 12.11 OTHERS CHAPTER 14 APPENDIX
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(二次医療)の最新刊レポート
Market Research Future社の二次医療分野での最新刊レポート
本レポートと同じKEY WORD()の最新刊レポート
よくあるご質問Market Research Future社はどのような調査会社ですか?マーケットリサーチフューチャー(Market Research Future)は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。 下記分野については、分野毎に専... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |